Mantle Cell Lymphoma
Conditions
Keywords
Lenalidomide, Mantle Cell Lymphoma, Relapsed, Refractory, RRMCL spanish program
Brief summary
This is a multicentric, observational and retrospective study of the use of lenalidomide in patients with relapsed or refractory mantle cell lymphoma that are included in the RRMCL spanish program. The lenalidomide effectiveness and tolerability data will be retrospectely collected until the 30 of April 2018.
Interventions
DRUGLenalidomide
Lenalidomide effectiveness and tolerability data analysis, that will be retrospectively collected until the 30 of April 2018.
Sponsors
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* ≥ 18 years old. * Diagnosed with relapsed or refractory mantle cell lymphoma verified by a tissue biopsy. * Treated with monotherapy or combination of lenalidomide. * Not candidate for any of the therapeutic options approved until that date for this disease. * Not candidate or unable to be included in any clinical trial due to availability or geographical difficulty. * Registered in the RRMCL spanish program.
Exclusion criteria
* ECOG \> 2. * Patients with uncontrolled comorbidities. * Blastoid variant. * Central nervous system tumor infiltration. * HIV, HBV and/or HCV active infection. * Radiotherapy concomitant treatment or that have received radiotherapy in the previous 30 days to the beginning of the first cycle of lenalidomide. * Diagnosed with other active solid tumor except for basal cell carcinoma skin cancer. * Patients that haven´t completed at least one complete cycle of the treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Experience of real clinal practice lenalidomide use. | Start of observation period (first medical record available on site) up to last medical record available on site or the end of the observation period (31 December 2019), whichever occurred first | Results of the the usage in real clinical practice of the lenalidomide monotherapy or combination treatment in patients with relapsed or refractory mantle cell lymphoma that aren´t candidate to other alternative treatments inside the RRMCL spanish program. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients that achieve objective response. | Start of observation period (first medical record available on site) up to last medical record available on site or the end of the observation period (31 December 2019), whichever occurred first | The objective response will be measured in terms of complete response, not confirmed complete response and partial response according to the 2007 International Working Group criteria after the 6º treatment cycle. |
| Duration of the response. | Start of observation period (first medical record available on site) up to last medical record available on site or the end of the observation period (31 December 2019), whichever occurred first | Partial and complete response duration. |
| Verify the disease free survival. | Start of observation period (first medical record available on site) up to last medical record available on site or the end of the observation period (31 December 2019), whichever occurred first | The disease free survival is defined as the time that passes from the inclusion in the record until a control is done or takes place a relapse (local or distant). |
| Verify the disease overall survival. | Start of observation period (first medical record available on site) up to last medical record available on site or the end of the observation period (31 December 2019), whichever occurred first | The disease overall survival is defined as the time that passes from the inclusion in the record until a control is done or the patient´s death. |
| Evaluate the incidence of treatment adverse events. | Start of observation period (first medical record available on site) up to last medical record available on site or the end of the observation period (31 December 2019), whichever occurred first | Number and description of adverse effects due to the lenalidomide treatment. |
Countries
Spain
Contacts
Primary ContactCarlos García Pérez
Outcome results
None listed